Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
Early intervention is important in many illnesses, including psychosis, so treatment can begin as early as possible for best outcomes, explained Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University. He also discussed a resource for learning more about early intervention.
Transcript
Why is early recognition and intervention for young people with psychosis so important?
Well, early intervention for psychosis is important because we want to begin treatment at the earliest stage of illness. Just like we would want to begin treatment for cancer at the earliest stage of illness, there’s no reason to want to wait until far longer before somebody begins treatment. We know that the duration of untreated psychosis correlates with treatment outcome, and in the United States in the RAISE-ETP study we saw that the median duration of untreated psychosis was 74 weeks. We need to make that sooner so that people get into treatment earlier and achieve better outcomes.
What are some resources for clinicians seeking to learn more about early intervention in psychosis?
I’m excited to present a new book on intervening early in psychosis that I wrote with my coauthors Dr Hardy, Dr Noordsy, and Dr Adelsheim. The book is available through the APA Press and through Amazon, and it provides a comprehensive look for all members of the treatment team in treating early psychosis. It’s written through using case vignettes and other ways to help people to appreciate all of the different aspects in intervening early in psychosis. There’s been a tremendous increase in early intervention clinics, but many people are wondering exactly what that should look like. This book will help provide a comprehensive look on all of the different factors that one should consider when developing a comprehensive treatment for early psychosis.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More